Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zymeworks Inc
(NQ:
ZYME
)
14.42
+0.12 (+0.84%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zymeworks Inc
In-Depth Examination Of 9 Analyst Recommendations For Zymeworks
November 22, 2024
Via
Benzinga
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework
November 21, 2024
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone.
Via
Benzinga
Exposures
Product Safety
Zymeworks Announces Participation in Upcoming Investor Conferences
November 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
November 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
What Analysts Are Saying About Zymeworks Stock
October 22, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Zymeworks
June 06, 2024
Via
Benzinga
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
November 07, 2024
Via
Benzinga
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
November 05, 2024
Global Phase 1 clinical trial will evaluate the safety and tolerability of ZW191 in treatment of advanced cancers including ovarian, endometrial, and non-small cell lung cancers
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
October 29, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
October 25, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
October 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
October 10, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
September 18, 2024
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate development platforms
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
September 03, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
August 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
August 01, 2024
Zymeworks intends to commence the Share Repurchase Program with $30.0 million in initial repurchases anticipated to begin promptly and continue during the second half of 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
July 30, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
July 25, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
July 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
July 11, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
June 17, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Week In Review: Osaka Enters $445 Million Deal For Two Hearing Loss Candidates From France's Cilcare
June 15, 2024
Shionogi, an Osaka innovative pharma, has signed an option agreement with Cilcare of France to in-license two drug candidates aimed at hearing loss in a deal worth up to $445 million. Meanwhile, XtalPi...
Via
Talk Markets
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
June 10, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.